[go: up one dir, main page]

MX2023004731A - Forma cristalina iv del compuesto agonista de receptor de melanocortina y metodo de preparacion para la misma. - Google Patents

Forma cristalina iv del compuesto agonista de receptor de melanocortina y metodo de preparacion para la misma.

Info

Publication number
MX2023004731A
MX2023004731A MX2023004731A MX2023004731A MX2023004731A MX 2023004731 A MX2023004731 A MX 2023004731A MX 2023004731 A MX2023004731 A MX 2023004731A MX 2023004731 A MX2023004731 A MX 2023004731A MX 2023004731 A MX2023004731 A MX 2023004731A
Authority
MX
Mexico
Prior art keywords
crystal form
preparation
method therefor
receptor agonist
melanocortin receptor
Prior art date
Application number
MX2023004731A
Other languages
English (en)
Inventor
Sang Dae Lee
Sung Won Kim
Ji Yoon Kim
Ho Yeon Lee
Jin Ok Ham
Seul Ah Chun
Jong Won Park
Original Assignee
Lg Chemical Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lg Chemical Ltd filed Critical Lg Chemical Ltd
Publication of MX2023004731A publication Critical patent/MX2023004731A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/14—Nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La presente invención se relaciona a una forma cristalina IV representada por la fórmula 1, un método para preparar la misma, y una composición farmacéutica que comprende la misma. La forma cristalina IV representada por la fórmula 1 de la presente invención se puede caracterizar mediante patrones XRD, perfiles DSC y/o perfiles TGA.
MX2023004731A 2020-10-29 2021-10-29 Forma cristalina iv del compuesto agonista de receptor de melanocortina y metodo de preparacion para la misma. MX2023004731A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20200142400 2020-10-29
PCT/KR2021/015475 WO2022092914A1 (ko) 2020-10-29 2021-10-29 멜라노코르틴 수용체 작용제 화합물의 결정형 ⅳ 및 이의 제조방법

Publications (1)

Publication Number Publication Date
MX2023004731A true MX2023004731A (es) 2023-05-10

Family

ID=81384123

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023004731A MX2023004731A (es) 2020-10-29 2021-10-29 Forma cristalina iv del compuesto agonista de receptor de melanocortina y metodo de preparacion para la misma.

Country Status (14)

Country Link
US (1) US20240010633A1 (es)
EP (1) EP4219475A4 (es)
JP (2) JP2023548161A (es)
KR (2) KR102672627B1 (es)
CN (1) CN116507614A (es)
AU (1) AU2021367714B2 (es)
CA (1) CA3195328A1 (es)
CL (1) CL2023001225A1 (es)
CO (1) CO2023006521A2 (es)
IL (1) IL302429A (es)
MX (1) MX2023004731A (es)
PE (1) PE20240367A1 (es)
WO (1) WO2022092914A1 (es)
ZA (1) ZA202305590B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI754448B (zh) * 2019-11-07 2022-02-01 南韓商Ｌｇ化學股份有限公司 黑皮質素-4受體激動劑
EP4249485A4 (en) * 2020-12-22 2024-05-15 Lg Chem, Ltd. CRYSTALLINE FORM III OF A MELANOCORTIN RECEPTOR AGONIST COMPOUND AND METHOD OF PREPARING THE SAME
TWI814185B (zh) * 2020-12-22 2023-09-01 南韓商Ｌｇ化學股份有限公司 黑皮質素受體促效劑化合物之晶型ii及其製備方法
AU2021409684B2 (en) * 2020-12-22 2025-06-26 Lg Chem, Ltd. Use as selective agonist of malanocortin-4 receptor
JP2024500966A (ja) * 2020-12-22 2024-01-10 エルジー・ケム・リミテッド メラノコルチン受容体アゴニスト化合物の結晶形ｉおよびその製造方法
KR102854596B1 (ko) * 2021-05-06 2025-09-03 주식회사 엘지화학 멜라노코르틴 수용체 작용제 화합물의 결정형 ⅶ 및 이의 제조방법
AU2022271119A1 (en) * 2021-05-06 2023-11-02 Lg Chem, Ltd. Crystalline form v of melanocortin receptor agonist compound, and method for preparing same
WO2022235103A1 (ko) * 2021-05-07 2022-11-10 주식회사 엘지화학 멜라노코르틴 수용체 작용제 화합물의 황산염의 결정형 및 이의 제조방법
EP4317151A4 (en) * 2021-05-07 2024-10-30 Lg Chem, Ltd. CRYSTAL FORM IV OF ORGANIC ACID SALTS OF A MELANOCORTIN RECEPTOR AGONIST COMPOUND AND METHOD OF PREPARING THE SAME
JP2024516739A (ja) * 2021-05-07 2024-04-16 エルジー・ケム・リミテッド メラノコルチン受容体アゴニスト化合物とバニリンの共結晶およびその製造方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003505435A (ja) * 1999-06-04 2003-02-12 メルク エンド カムパニー インコーポレーテッド メラノコルチン−４受容体ゴニストとしての置換ピペリジン
JP2004521117A (ja) * 2001-01-23 2004-07-15 イーライ・リリー・アンド・カンパニー メラノコルチン受容体アゴニストとしての置換ピペリジン／ピペラジン
AR044510A1 (es) 2003-04-14 2005-09-14 Merck & Co Inc Procedimiento e intermedios para preparar acidos carboxilicos de pirrolidina
TWI341835B (en) * 2003-11-12 2011-05-11 Lg Life Sciences Ltd Melanocortin receptor agonists
TWI332501B (en) * 2006-07-14 2010-11-01 Lg Life Sciences Ltd Melanocortin receptor agonists
KR20080007046A (ko) * 2006-07-14 2008-01-17 주식회사 엘지생명과학 멜라노코틴 수용체의 항진제
UA99555C2 (en) * 2008-11-12 2012-08-27 Элджи Лайф Саенсез Лтд. Melanocortin receptor agonists
AU2018219880A1 (en) 2017-02-08 2019-08-29 Tilray, Inc. Methods and apparatus for low-pressure radiant energy processing of cannabis
TWI754448B (zh) * 2019-11-07 2022-02-01 南韓商Ｌｇ化學股份有限公司 黑皮質素-4受體激動劑

Also Published As

Publication number Publication date
CL2023001225A1 (es) 2023-11-03
AU2021367714A1 (en) 2023-06-01
CA3195328A1 (en) 2022-05-05
KR20240085233A (ko) 2024-06-14
WO2022092914A1 (ko) 2022-05-05
CO2023006521A2 (es) 2023-08-18
IL302429A (en) 2023-06-01
PE20240367A1 (es) 2024-03-04
ZA202305590B (en) 2024-09-25
JP2025098275A (ja) 2025-07-01
KR102672627B1 (ko) 2024-06-07
US20240010633A1 (en) 2024-01-11
JP2023548161A (ja) 2023-11-15
EP4219475A4 (en) 2024-03-13
CN116507614A (zh) 2023-07-28
AU2021367714B2 (en) 2024-01-25
EP4219475A1 (en) 2023-08-02
KR20220057473A (ko) 2022-05-09

Similar Documents

Publication Publication Date Title
ZA202305590B (en) Crystal form iv of melanocortin receptor agonist compound, and preparation method therefor
ZA202305595B (en) Crystal type ii of melanocortin receptor agonist compound and method for preparing same
ZA202305593B (en) Crystalline form iii of melanocortin receptor agonist compound and method for preparing same
MX2023004655A (es) Forma cristalina i del compuesto agonista de receptor de melanocortina y metodo de preparacion para la misma.
ZA202305591B (en) Amorphous melanocortin-4 receptor agonist
ZA202306748B (en) Glp-1r receptor agonist compound and use thereof
ZA202000411B (en) Polymorphs of 5-fluoro-4-imino-3-methyl-1-tosyl-3,4-dihydropyrimidin-2-one
NO20092762L (no) 2-aza-bicyklo[3.1.0]heksanderivater
UA97478C2 (ru) Кристаллическая форма vi агомелатина, способ ее приготовления (варианты) и фармацевтическая композиция, которая ее содержит
TNSN07255A1 (en) Cyclohexylamides as dopamine d3, d2 and 5ht 1a antagonists
UA100669C2 (ru) Спироциклические нитрилы как ингибиторы протеазы, способ их получения (варианты) и лекарственное средство на их основе
EA200600323A1 (ru) γd-КРИСТАЛЛИЧЕСКАЯ ФОРМА ГИДРОХЛОРИДА ИВАБРАДИНА, СПОСОБ ЕЁ ПОЛУЧЕНИЯ И ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, КОТОРЫЕ ЕЁ СОДЕРЖАТ
GEP20094577B (en) New crystalline form iv of agomelatine, a process for its preparation and pharmaceutical compositions containing it
MY194364A (en) Polymorphic Forms of Kinase Inhibitor Compound, Pharmaceutical Composition Containing Same, Preparation Method Therefor and use Thereof
GEP20094576B (en) New cyrstalline form iii of agomelatine, a process for its preparation and pharmaceutical compositions containing it
MX2023013044A (es) Forma cristalina v del compuesto agonista del receptor de melanocortina y metodo para preparar la misma.
GEAP202215389A (en) Polymorphs
BR112023022863A2 (pt) Forma cristalina vii do composto agonista do receptor de melanocortina e método para preparar o mesmo
MX2023013128A (es) Cristales de sulfato de compuesto agonista del receptor de melanocortina, y metodo para producir los mismos.
TW200745090A (en) Chemical compounds
GEP20125386B (en) Pyrazole analogs
MX2023013129A (es) Forma cristalina iv de sales de acidos organicos del compuesto agonista del receptor de melanocortina y metodo de preparacion de este.
MX2023013803A (es) Sal farmaceuticamente aceptable del derivado de pirazoloheteroarilo y forma cristalina del mismo.
WO2008092928A3 (de) NEUE ß-LACTAM-ANTIBIOTIKA, VERFAHREN ZU IHRER HERSTELLUNG UND IHRE VERWENDUNG
NZ599916A (en) 5-amino-4-hydroxypentoyl amides